HOME > Detail View

Detail View

Medicinal chemistry of anticancer drugs [electronic resource] / 2nd ed

Medicinal chemistry of anticancer drugs [electronic resource] / 2nd ed

Material type
E-Book(소장)
Personal Author
Avendaño, Carmen. Menéndez, J. Carlos (José Carlos).
Title Statement
Medicinal chemistry of anticancer drugs [electronic resource] / by Carmen Avendaño and J. Carlos Menéndez.
판사항
2nd ed.
Publication, Distribution, etc
Amsterdam :   Elsevier Science,   c2015.  
Physical Medium
1 online resource (767 p.).
ISBN
9780444626493 0444626492 9780444626677 0444626670
General Note
Title from e-Book title page.  
Includes index.  
이용가능한 다른형태자료
Issued also as a book.  
Subject Added Entry-Topical Term
Cancer --Chemotherapy. Drugs --Design. Pharmaceutical chemistry. Drug Design. Chemistry, Pharmaceutical.
Short cut
ScienceDirect   URL
000 00000cam u2200205 a 4500
001 000045987296
005 20190621163140
006 m d
007 cr
008 190619s2015 ne o 001 0 eng d
015 ▼a GBB6G6316 ▼2 bnb
020 ▼a 9780444626493
020 ▼a 0444626492
020 ▼a 9780444626677
020 ▼a 0444626670
035 ▼a (OCoLC)911246573
040 ▼a EBLCP ▼b eng ▼e pn ▼c EBLCP ▼d OPELS ▼d E7B ▼d UIU ▼d UV0 ▼d OCLCF ▼d OCLCQ ▼d BUF ▼d OCLCO ▼d MERER ▼d OCLCO ▼d OCLCQ ▼d U3W ▼d OCLCO ▼d D6H ▼d UKMGB ▼d WYU ▼d OCLCO ▼d OCLCA ▼d 211009
050 1 4 ▼a RC271.C5
082 0 4 ▼a 616.99/4061 ▼2 23
084 ▼a 616.994061 ▼2 DDCK
090 ▼a 616.994061
100 1 ▼a Avendaño, Carmen.
245 1 0 ▼a Medicinal chemistry of anticancer drugs ▼h [electronic resource] / ▼c by Carmen Avendaño and J. Carlos Menéndez.
250 ▼a 2nd ed.
260 ▼a Amsterdam : ▼b Elsevier Science, ▼c c2015.
300 ▼a 1 online resource (767 p.).
500 ▼a Title from e-Book title page.
500 ▼a Includes index.
530 ▼a Issued also as a book.
538 ▼a Mode of access: World Wide Web.
650 0 ▼a Cancer ▼x Chemotherapy.
650 0 ▼a Drugs ▼x Design.
650 0 ▼a Pharmaceutical chemistry.
650 2 ▼a Drug Design. ▼0 (DNLM)D015195.
650 2 ▼a Chemistry, Pharmaceutical. ▼0 (DNLM)D002626.
700 1 ▼a Menéndez, J. Carlos ▼q (José Carlos).
856 4 0 ▼3 ScienceDirect ▼u https://oca.korea.ac.kr/link.n2s?url=http://www.sciencedirect.com/science/book/9780444626493
945 ▼a KLPA
991 ▼a E-Book(소장)

Holdings Information

No. Location Call Number Accession No. Availability Due Date Make a Reservation Service
No. 1 Location Main Library/e-Book Collection/ Call Number CR 616.994061 Accession No. E14013697 Availability Loan can not(reference room) Due Date Make a Reservation Service M

Contents information

Table of Contents

Front Cover -- Medicinal Chemistry of Anticancer Drugs -- Copyright -- Contents -- Foreword -- Preface -- Abbreviations -- Chapter 1: General Aspects of Cancer Chemotherapy -- 1. Introduction: Some General Comments About Cancer -- 2. Tumorigenesis and Oncogenes: Pharmacogenomics -- 3. Early Diagnosis of Cancer and Its Therapeutic Relevance -- 4. A Brief History of Cancer Chemotherapy -- 5. General Comments About Anticancer Drug Discovery -- 6. Combination Therapy and Personalized Anticancer Treatments -- 7. Natural Products in Cancer Chemotherapy -- 8. A Brief Comment About Cancer Nanotechnology -- 9. Summary of FDA-Approved Anticancer Drugs -- References -- Chapter 2: Antimetabolites That Interfere with Nucleic Acid Biosynthesis -- 1. Introduction -- 2. Inhibitors of the Biosynthesis of Uridylic Acid -- 3. Inhibitors of Ribonucleotide Reductase -- 3.1. Structure and Catalytic Cycle of Ribonucleotide Reductase -- 3.2. Gallium Salts and Complexes -- 3.3. Radical Scavengers -- 3.4. Substrate Analogs as Ribonucleotide Reductase Inhibitors -- 3.5. Allosteric Inhibition of Ribonucleotide Reductase via Inhibition of Purine Nucleoside Phosphorylase -- 4. Inhibitors of the Biosynthesis of Thymidilic Acid -- 4.1. Thymidylate Synthase -- 4.2. 5-Fluorouracil and Floxuridine -- 4.3. 5-Fluorouracil Prodrugs -- 4.4. Modulation of 5-Fluorouracil Activity -- 4.4.1. Decreased Degradation of 5-FU -- 4.4.2. Enhancement of the Inhibition of Thymidylate Synthase by 5-FU -- 4.4.3. Enhancement of 5-FU Activation -- 4.5. Trifluridine -- 4.6. Folate-Based Thymidylate Synthase Inhibitors -- 5. Inhibitors of Dihydrofolate Reductase -- 5.1. Classical DHFR Inhibitors -- 5.2. Nonclassical (Lipophilic) DHFR Inhibitors -- 6. Inhibitors of the De Novo Purine Biosynthesis Pathway -- 6.1. Inhibitors of PRPP Amidotransferase -- 6.2. Inhibitors of Glycinamide Ribonucleotide Formyltransferase -- 6.3. Inhibitors of Phosphoribosylformylglycinamidine Synthetase -- 6.4. Inhibitors of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase -- 6.5. Thiopurines and Related Compounds -- 7. Inhibitors of Adenosine Deaminase -- 8. Inhibitors of Late Stages in DNA Synthesis -- 8.1. Pyrimidine Nucleosides -- 8.2. Purine Nucleosides -- 9. Antimetabolite Enzymes -- References -- Chapter 3: Anticancer Drugs That Modulate Hormone Action -- 1. Introduction -- 2. Estrogens and Their Involvement in Carcinogenesis -- 3. Antiestrogens as Antitumor Drugs -- 3.1. Nonsteroidal Antiestrogens (Selective Estrogen Receptor Modulators) -- 3.2. Steroidal Antiestrogens -- 4. Aromatase Inhibitors -- 4.1. Aromatase Mechanism of Action -- 4.2. Steroidal Aromatase Inhibitors (Type I Inhibitors) -- 4.3. C-19 Modified Substrate Analogs -- 4.4. 4-Hydroxyandrostenedione Derivatives -- 4.5. Steroids with Additional Unsaturations at the A and B Rings -- 4.6. Structure-Activity Relationships in Steroidal Aromatase Inhibitors -- 4.7. Nonsteroidal Aromatase Inhibitors (Type II) -- 5. Steroid Sulfatase Inhibitors -- 6. .
Androgen-Related Antitumor Agents -- 6.1. Antiandrogens -- 6.1.1. Steroidal Antiandrogens -- 6.1.2. Nonsteroidal Antiandrogens -- 6.2. Inhibitors of Androgen Biosynthesis -- 6.2.1. Inhibitors of 14α-Demethylase -- 6.2.2. Inhibitors of CYP17A1 (17α-hydroxylase and C(17,20)-lyase) -- 6.2.3. Inhibitors of 5α-Reductase -- 7. Regulation of Gonadotropin-Releasing Hormone: Control of the Hypothalamic-Pituitary-Gonadal axis -- 7.1. Introduction -- 7.2. GnRH (LHRH) Agonists -- 7.3. GnRH (LHRH) Antagonists -- 8. Miscellaneous Steroid Hormone-Related Anticancer Therapy -- 8.1. Gestagens as Antitumor Agents -- 8.2. Glucocorticoids and Inhibitors of Their Biosynthesis as Antitumor Agents -- 9. Compounds Acting on Other Proteins of the Nuclear Receptor Superfamily: Retinoids -- 10. PPAR Ligands as Antitumor Agents -- 11. Somatostatin Analogs in Neuroendocrine Tumors -- References -- Chapter 4: Anticancer Drugs Acting via Radical Species: Radiotherapy and Photodynamic Therapy of Cancer -- 1. Introduction: Radicals and Other Reactive Oxygen Species -- 2. Biological Effects of Reactive Oxygen Species -- 2.1. Membrane Phospholipid Peroxidation -- 2.2. Malondialdehyde Generation and Its Consequences -- 2.3. DNA Strand Cleavage -- 2.4. Oxidation of DNA Bases -- 2.5. Formaldehyde Generation -- 2.6. ROS as Signaling Molecules -- 2.7. Oxidative Stress Induction as a Strategy in Cancer Treatment -- 3. Anthracyclines and Their Analogs -- 4. Mitoxantrone and Related Quinones -- 5. Actinomycin D -- 6. Chartreusin, Elsamicin A, and Related Compounds -- 7. Bleomycins -- 8. Enediyne Antibiotics -- 9. Tirapazamine -- 10. Penclomedine -- 11. Radiotherapy and Radiosensitizers -- 11.1. Radiotherapy -- 11.1.1. External Beam Radiotherapy -- 11.1.2. Brachytherapy (Internal Radiation Therapy) -- 11.1.3. Radioisotope Therapy -- 11.1.4. Neutron Irradiation -- 11.2. Drugs Used to Improve the Results of Radiotherapy -- 11.2.1. Radiosensitizers -- 11.2.2. Oxygen Enhancement for Radiosensitization -- 11.2.3. Radioprotectors in Radiotherapy -- 12. Photodynamic Therapy of Cancer -- 12.1. Porphyrins as Photosensitizers -- 12.2. Non-porphyrin Photosensitizers -- 12.3. Other Applications of Photodynamic Therapy -- References -- Chapter 5: DNA Alkylating Agents -- 1. Introduction -- 2. Nitrogen Mustards -- 2.1. Introduction -- 2.2. DNA Alkylation by Nitrogen Mustards and Cytotoxicity Mechanisms -- 2.3. Structure-Activity Relationships in Nitrogen Mustards -- 2.4. Site-Directed Nitrogen Mustards -- 3. Aziridines (Ethyleneimines) -- 4. Epoxides -- 5. Methanesulfonates -- 6. Nitrosoureas -- 7. Triazenes -- 8. Methylhydrazines -- 9. 1,3,5-Triazines: Hexamethylmelamine and Trimelamol -- 10. Transition Metal Species -- 10.1. Platinum Complexes -- 10.2. Ruthenium Complexes -- 10.3. Titanocenes -- 11. Miscellaneous Alkylating and Acylating Antitumor Agents -- References -- Chapter 6: Anticancer Drugs that Interact with the DNA Minor Groove -- 1. Introduction -- 2. Netropsin, Distamycin, and Related Comp.
ounds -- 3. Mitomycins -- 4. Tetrahydroisoquinoline Alkaloids -- 5. Cyclopropylindole Alkylating Agents -- 6. Irofulven -- 7. Pyrrolo[1,4]benzodiazepines -- References -- Chapter 7: Other Anticancer Drugs Targeting DNA and DNA-Associated Enzymes -- 1. DNA Intercalation and Its Consequences -- 2. Monofunctional Intercalating Agents -- 2.1. Ellipticine and Its Analogs -- 2.2. Actinomycins -- 2.3. Fused Quinolines -- 2.4. Naphthalimides and Related Compounds -- 2.5. Chartreusin, Elsamicin A, and Related Compounds -- 2.6. Other Monofunctional Intercalating Agents -- 3. Bifunctional Intercalating Agents -- 4. Indirect DNA Damage by DNA Topoisomerase Inhibitors -- 4.1. Topoisomerase I Mechanism -- 4.2. Topoisomerase II Mechanism -- 5. Specific Topoisomerase I Inhibitors -- 5.1. Camptothecins -- 5.2. Non-camptothecin Topoisomerase I Inhibitors -- 6. Topoisomerase II Poisons -- 6.1. Acridine Derivatives -- 6.2. Anthracyclines and Related Compounds -- 6.3. Non-intercalating Topoisomerase II Poisons -- 6.3.1. Etoposide and Its Analogs -- 6.3.2. Salvicine -- 7. Topoisomerase II Catalytic Inhibitors -- 7.1. Inhibitors of the Binding of Topoisomerase II to DNA -- 7.1.1. Aclarubicin -- 7.1.2. Merbarone -- 7.1.3. Bis(dioxopiperazines) -- 8. Telomerase Inhibitors and Other Anticancer Approaches Targeting Telomeres -- 8.1. G-Quadruplex Ligands -- 8.2. Inhibitors of Telomerase Reverse Transcriptase -- 8.3. Inhibitors of the RNA Domain Template -- 9. DNA Repair Inhibitors -- References -- Chapter 8: Epigenetic Therapy of Cancer -- 1. Introduction -- 2. Inhibitors of DNA Methylation: Reactivation of Silenced Genes -- 2.1. Nucleoside Inhibitors of DNA Methyltransferases -- 2.2. Non-nucleoside Inhibitors of DNA Methyltransferase -- 3. Inhibitors of Histone and Other Protein Deacetylases -- 3.1. Short-Chain Fatty Acids -- 3.2. Hydroxamic Acids -- 3.3. Cyclic Tetrapeptides -- 3.4. Benzamides -- 3.5. Thiols -- 3.6. Inhibitors of HDAC4 -- 3.7. Inhibitors of Sirtuins -- 3.8. Bromodomain Inhibitors -- 4. Regulators of Histone Methylation -- 4.1. Inhibitors of Histone Methyltransferases -- 4.2. Lysine-Specific Demethylases (LSDs or KDMs) and Their Inhibitors -- References -- Chapter 9: Anticancer Drugs Targeting Tubulin and Microtubules -- 1. Introduction -- 2. Drugs That Inhibit Microtubule Polymerization -- 2.1. Compounds Binding at the Vinca Site -- 2.1.1. Vinca Alkaloids and Their Synthetic Analogs -- 2.1.2. Marine Natural Products Binding at the Vinca Domain and Their Analogs -- 2.2. Compounds Binding at the Colchicine Site -- 3. Microtubule-Stabilizing Agents: Compounds Binding at the Taxane Site -- 3.1. Taxanes -- 3.2. Epothilones -- 3.3. Miscellaneous Marine Compounds That Bind to the Taxane Site -- 3.4. Inhibitors of LIM Kinase -- 4. Miscellaneous Anticancer Drugs Acting on Novel Sites of Tubuline -- 5. Antivascular Effects of Microtubule-Targeted Agents -- 6. Mitotic Kinesin Inhibitors -- References -- Chapter 10: Drugs that Inhibit Signaling Pathways for Tumor Cel.

New Arrivals Books in Related Fields

대한모발학회 교과서편찬위원회 (2021)
이영실 (2020)
대한배뇨장애요실금학회 (2021)
Amin, Mahul B. (2021)